ACRS - Aclaris Therapeutics GAAP EPS of -$0.42 beats by $0.02 revenue of $2.53M beats by $0.78M
2023-05-08 07:03:04 ET
- Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q1 GAAP EPS of -$0.42 beats by $0.02 .
- Revenue of $2.53M (+74.5% Y/Y) beats by $0.78M .
- The increase was driven by higher licensing revenue primarily from royalties earned on out-licensed intellectual property in the first quarter of 2023.
For further details see:
Aclaris Therapeutics GAAP EPS of -$0.42 beats by $0.02, revenue of $2.53M beats by $0.78M